NEWS & EVENTS

Latest news and upcoming events

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial
25 May 2023

VarmX raises €30 million Series B2 financing for IND approval and preparations for pivotal trial

Upcoming events

  • Biospain
    26 - 28 September 2023,
    Barcelona

    download

  • Bio€quity Europe
    14 - 16 May 2023,
    Dublin

    download

  • Swiss Biotech Day
    24 - 25 April 2023,
    Switzerland

    download
Babyscripts and MemorialCare Mark Three-year Partnership with Significant Results in Blood Pressure Risk Identification and Patient Engagement in Maternal Populations<
11 May 2023

Babyscripts and MemorialCare Mark Three-year Partnership with Significant Results in Blood Pressure Risk Identification and Patient Engagement in Maternal Populations

Role will drive growth, focus Babyscripts’ strategic expansion in payer and provider markets
Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update<
10 May 2023

Kala Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Corporate Update

Awarded $15 million grant from CIRM to support the KPI-012 PCED program
Babyscripts Welcomes New Executive VP of Revenue Andrew Reeve<
03 May 2023

Babyscripts Welcomes New Executive VP of Revenue Andrew Reeve

Role will drive growth, focus Babyscripts’ strategic expansion in payer and provider markets
Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension<
02 May 2023

Mineralys Therapeutics Announces First Patient Dosed in the ADVANCE-HTN Pivotal Trial of Lorundrostat for the Treatment of Uncontrolled and Resistant Hypertension

Topline data from the trial are expected in the first half of 2024 
Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress<
28 Apr 2023

Xeltis presents excellent six-month first-in-human data from aXess hemodialysis vascular graft trial at Vascular Access Society Congress

Use of proceeds to advance Xeltis’ aXess vascular access graft into pivotal clinical trials
SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023<
27 Apr 2023

SparingVision Presents Progress of its Lead Gene Therapy Program SPVN06 at ARVO 2023

Data demonstrated the absorption and shedding of SPVN06, which was transiently observed in blood and tears, and high tropism for the retina
Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)<
25 Apr 2023

Minoryx presents positive interim results from NEXUS registration study for leriglitazone targeting pediatric ALD patients with cerebral adrenoleukodystrophy (cALD)

Initial evidence of disease stabilization was demonstrated for all patients using radiological, clinical and plasma biomarker assessments at 6 months (24 weeks) of treatment
Anaconda Biomed Names New Chairperson, Appoints Chief Medical Officer<
20 Apr 2023

Anaconda Biomed Names New Chairperson, Appoints Chief Medical Officer

Company Appoints De Novo Ventures Co-Founder Richard Ferrari as Chairperson, and Names Hendrik Lambert, PhD., as Chief Medical Officer
Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting<
13 Apr 2023

Adcendo ApS to Present Data on the Expression of the Novel ADC target uPARAP in Soft Tissue and Bone Sarcoma at the 2023 American Association for Cancer Research (AACR) Annual Meeting

Data demonstrate that uPARAP is widely expressed at high levels across multiple sarcoma subtypes
Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect<
12 Apr 2023

Kala Pharmaceuticals Receives FDA Fast Track Designation for KPI-012, a Human MSC-S Therapy for Persistent Corneal Epithelial Defect

Fast Track designation for Kala’s human mesenchymal stem cell secretome (MSC-S) therapy or the treatment of persistent corneal epithelial defect

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.